Cardiovascular Effects of Androgens by Carlos Wilson et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
Cardiovascular Effects of Androgens 
Carlos Wilson, Rodrigo Maass and Manuel Estrada 
Universidad de Chile, Facultad de Medicina, Instituto de Ciencias Biomédicas 
Chile 
1. Introduction 
Androgens are the male sex hormones responsible for development of the male 
reproductive system. Testosterone is the main androgen, however, other circulating 
androgens also exist; these are dehydroepiandrosterone, androstenedione and 
androstenediol. In some tissues, testosterone can be converted to dihydrotestosterone by 
action of 5┙-reductase. Testosterone is also found in females, but at much lower levels than 
males; it can be converted into estradiol by the enzyme aromatase. Testosterone has 19 
carbon atoms, and is produced from cholesterol, mainly by Leydig cells in the testes. 
Androgens are responsible for primary and secondary sexual characters in men, and also for 
the development of skeletal muscle mass and strength, erythropoiesis and bone density, 
amongst other functions. 
The divergent effects that androgens have between sexes can be explained by differences in 
concentration, metabolism and receptor expressions. Male sex hormones are also known to 
fluctuate along the day and throughout life. Prior to puberty, testosterone level is usually 
low in males. However, after puberty, testosterone level increases and reaches its peak 
around the age of 20-25 in men. As aging occurs, testosterone levels decline. 
Testosterone and its derivatives are well known for their androgenic properties and anabolic 
effects. These hormones direct the differentiation of organs and tissues towards the 
adoption of male phenotypes. Thus far, the effects of androgens on the cardiovascular 
system remain incompletely understood. Some studies point to increased cardiovascular 
risk associated with a high circulating androgen level, related to responses that lead to 
changes in blood pressure, ion channel activity and cardiomyocyte hypertrophy. However, 
other studies support a long-term cardio-protective role for these steroid hormones. Despite 
these differences, increasing clinical evidence supports consideration for transient use of 
testosterone derivatives to improve cardiovascular function. 
2. Mechanism of androgen action 
Androgens exert most their effects through the direct binding to specific intracellular 
receptors acting as transcriptional activators (Beato, 1989). Intracellular androgen receptors 
have been described in neonatal and adult cardiomyocytes (Hickson et al., 1984; Marsh et 
al., 1998). Genomic responses to testosterone are mediated through the intracellular 
androgen receptor, which is a 110-kDa protein with domains for androgen binding, nuclear 
localization, DNA binding, and transactivation (TD). The conserved domain structure has 
three major functional regions: an NH-terminal transactivation domain, a centrally located 
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DNA binding domain (DBD), and a COOH-terminal hormone-binding domain (HBD) 
(Figure 1). The COOH-terminus contains an additional activation domain and a hinge 
region connecting the HBD and the DBD. Upon ligand binding, the nuclear receptors 
translocate to the nucleus where they dimerize and bind to regulatory DNA sequences on 
target genes and activate transcription (Simental et al., 1992). Several co-regulatory proteins 
that bind and regulate the activity of receptors have been identified. These include both co-
activators that positively regulate transcriptional effects of intracellular receptors after 
ligand binding and co-repressors that negatively regulate receptor activity. These effects are 
slow, with a latency period before onset, but they are also long lasting, remaining active for 
hours after hormone stimulation. 
In addition to this transcriptional or genomic mode of action, increasing evidence suggests 
that androgens can exert rapid, non-genomic effects. The time course of these responses is 
not compatible with the classic genomic mechanism for the action of steroids, since they 
have a rapid onset without an apparent latency period. Common to these early effects is a 
fast increase in intracellular Ca2+ and activation of Ca2+-dependent pathways and second 
messenger cascades (Estrada et al., 2000, 2003). Second messenger induction by nongenomic 
steroid action is insensitive to inhibitors of either transcription or translation. Little is known 
about these non-genomic effects in cardiac cells. However, these responses involve the 
generation of different patterns of Ca2+ signals and also in the activation of complementary 
Ca2+-dependent pathways. Thus, in addition to the classical mechanism of steroid action in 
cardiac cells, androgens activate additional specific signal transduction pathways 
(Altamirano et al., 2009; Vicencio et al., 2006). An interesting hypothesis is that these second 
messenger cascades may ultimately serve to modulate the transcriptional activity of the 
intracellular androgen receptor and its associated global response. This idea of an integrated 
mechanism for androgen action will be discussed. 
 
 
Fig. 1. Schematic representation of testosterone and the main domains of intracellular 
androgen receptor. 
3. Cardiovascular effects of androgens 
Androgens influence cardiac function by acting directly on the heart or by affecting the 
vascular system (English et al., 2001; Hayward et al., 2001; Jones et al., 2003; Kienitz & 
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Quinkler, 2008). In humans and experimental animals, anabolic steroids have been 
associated with an increased risk of coronary artery disease by adversely affecting the 
plasma lipid and lipoprotein profile, producing thrombosis and cardiac hypertrophy (Liu et 
al., 2003; Sullivan et al., 1998). In particular, use of elevated doses of testosterone or its 
synthetic cognates has been related to cardiac hypertrophy, ventricular remodelling, 
cardiomyopathy, myocardial infarction, and sudden cardiac death. On the other hand, with 
a normal steroid level, androgen actions are necessary for a range of developmental and 
biological processes, including maintaining the health of cardiomyocytes. Androgens might 
also produce additional hemodynamic effects by relaxing vascular bed, reducing after-load 
and rapidly increasing cardiac contractility, resulting in increased cardiac output (Liu et al., 
2003). This dual androgen effect is not clear yet. Research in the field of androgens and 
androgen receptors signaling pathways will provide considerable understanding of the 
physiological and pathological roles of these hormones. These effects could be related to 
different concentrations of these hormones as well as to differential activation of signal 
transduction pathways. 
Both beneficial and pathological effects of androgens are observed clinically. Patients with 
chronic heart failure suffer considerable morbidity as well as early mortality. They exhibit 
altered structure and function of cardiac and skeletal muscle and excessive activation of 
catabolic hormones and inflammatory cytokines (Malkin et al., 2004). Men with chronic 
heart failure have relatively low androgen levels, which may contribute to the patho-
physiological process.  
3.1 Role of androgens in hypertension 
Hypertension is a major risk factor for developing cardiovascular disease, atherosclerosis 
and sudden cardiac death. Hypertension is more prevalent and occurs earlier in men than 
in women. Blood pressure is elevated from the onset of puberty in males, when they 
manifest the effects and differences of sex steroids. These differences in blood pressure 
between men and women are maintained until 60 years of age. Epidemiological data 
indicate that systolic blood pressure in men under the age of 60 years is 6-7 mm Hg higher 
than in women, and diastolic pressure is higher by 3-5 mm Hg (Stamler et al., 1976). In 
women over the age of 60, show gradual increases of blood pressure over a period of 5 to 
20 years, until hypertension is highly prevalent in women as in men. Estrogen reduction 
after menopause is partially responsible for this effect and experimental data indicate that 
the change in the estrogen/androgen ratio seems to be the cause (Akkad et al., 1997; Pripp 
et al., 1999). 
Epidemiological studies show that androgens are important determinants of sex differences 
in blood pressure. An elevated level of anabolic steroids, found in anabolic abuse by high 
performance athletes has been associated with hypertension, cardiac remodelling and 
myocardial ischemia (Kienitz & Quinkler, 2008). This suggests a direct role in the 
development of hypertension. However, clinical evidence shows beneficial effects of 
testosterone on hypertension. Observational studies in humans indicate that there is an 
inverse relationship between systolic pressure and the plasma level of testosterone in men. 
There is also higher incidence of hypertension in individuals with reduced free circulating 
androgen (Fogari et al., 2005). The beneficial effect of testosterone replacement has also been 
well documented. Accordingly, in randomized, double-blind, case-control clinical studies 
hormone administration was related to the reduction of vascular tone (Malkin et al., 2006). 
In other study, administration of testosterone significantly reduced ST segment depression 
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in patients with stable angina and improved post-exercise myocardial perfusion in patients 
with occlusive coronary artery disease (Jaffe, 1977).  
Furthermore, experimental evidences provide controversial information. In some animal 
models potential role for androgens in the pathogenesis of hypertension have been 
observed. Mice hypertension models show that castration and subsequent testosterone 
supplementation at high doses produce the onset of hypertension (Dubey et al., 2002). This 
effect is mediated by androgen receptors, as shown by the inhibitory effect of flutamide, an 
antagonist of the intracellular androgen receptor. However, others in vitro studies indicate a 
direct vasodilator effect of androgens by the activation of the nitric oxide (NO) pathway 
mediated by the endothelium, activation of voltage-dependent potassium channels and 
blockage of voltage and receptor-operated calcium channels (Jones et al., 2003, 2004). 
Thus, androgens appear to be involved in the regulation of vascular tone. Aging induces a 
progressive reduction in the plasma testosterone levels along the years, which begins to be 
deleterious as aging occurs; while physiological stress produces acute diminution of 
androgen levels. These conditions are determinants for clinical manifestation of 
hypertension. Therefore, testosterone supplementation in men with low levels of androgens 
could be beneficial to restore altered blood pressure (Handelsman & Liu, 2005). 
3.2 Androgens in endothelial function, atherosclerosis and heart perfusion 
Numerous clinical studies show that men exhibit higher susceptibility to atherosclerosis 
than pre-menopausal women. The available information indicate that the evolution of 
atherosclerosis is faster in males – independent of dyslipidemia or evidence of endothelial 
damage – than females (Kaushik et al, 2010.). However, a negative correlation between 
testosterone plasma level and cardiovascular disease in men has been observed (Iliescu & 
Reckelhoff, 2006; Thijs et al., 2003). Testosterone deficiency affects approximately 30% of 
men under 30 years and as aging occurs, testosterone level decline even more, a male 
condition known as andropause (Handelsman & Liu, 2005). Low androgen concentrations 
are strongly associated with increase in cardiovascular risks including atherogenic lipid 
profile, insulin resistance, obesity and prothrombotic profile (Jones et al., 2005; Kapoor et al., 
2007). However, other studies indicate that testosterone increases cholesterol uptake by 
macrophages promoting its transformation into foam cells, which are involved in the 
formation of atheroma lesions (McCrohon et al., 2000). Testosterone also induces apoptosis 
of endothelial cells in vitro and promotes proliferation and migration of vascular smooth 
muscle cells, which are involved in the development of atherosclerotic lesions (Kaushik et 
al., 2010). 
This appears to explain the faster progression of atherosclerosis occurring in men than 
women. However, the amount of clinical evidence suggests protective effects of androgens 
during atherosclerosis. For example, high to normal range of testosterone concentrations 
exhibit preventive role in coronary artery disease. In fact, patients with coronary artery 
disease show significantly lower testosterone level than patients without coronary artery 
disease (English et al., 2000). Animal models show similar results (Alexandersen et al., 1999). 
At cellular level, the mechanism for these testosterone effects involve inhibition of 
macrophage migration, which decrease the expression of adhesion molecules and pro-
inflammatory cytokines such as TNF┙ (Malkin et al., 2004). 
In addition, androgens produce direct and rapid vasodilatory effects in human coronary 
disease and stable angina, increasing the coronary flow between 12 and 17% (Webb et al., 
1999). This has not been free of controversy, because in isolated vessels the chronic 
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treatment with testosterone produce increase in the vasoconstrictor responses to adrenergic 
agonists, while reduce the response to nitric oxide (Iliescu & Reckelhoff, 2006; Malkin et al., 
2006). In animal models, testosterone produces a similar effect, independent of androgen 
receptor. Vasodilatation occurs by inhibition of plasma membrane calcium channels and 
activation of potassium channel (Ding & Stallone, 2001). However, this effect is acute and 
only produced in response to high doses of testosterone, so this does not appear to be an 
appropriate strategy for anti-ischemic treatment. But this could explain the positive effects 
on peripheral vascular resistance in response to acute administration of testosterone in men 
with heart failure, stable angina or in arteries isolated from healthy men with heart failure. 
Thus, current data indicate that androgens, particularly testosterone, do not have a 
permissive role in the evolution of atherosclerotic lesions at the cellular level. However, 
testosterone diminution as in aging is associated with accelerated atherosclerosis. This 
occurs by increase in the expression of adhesion molecules and pro-inflammatory cytokines. 
Moreover, this also could be stimulated by high exogenous androgen supplementation. 
3.3 Effects of testosterone on cardiac excitability 
Gender differences are well-established in the generation of ventricular arrhythmias 
associated with a prolonged QT interval. This interval is used to estimate the 
electrocardiographic duration of ventricular action potential. Thus, women exhibit greatest 
risk of ventricular arrhythmias such as “torsade de pointes”, a type of highly fatal 
polymorphic ventricular tachycardia. This clinical condition is worse in women compared 
with men, particularly in response to drugs that prolong the QT interval (Rautaharju et al., 
2006). This has been associated with sex differences in the rate of ventricular repolarization 
being slower in adult women. These differences are manifested from puberty, becoming the 
QT interval increasingly longer until women reach adulthood. In men, once they start to 
drop in plasma testosterone levels gradually prolong the QT interval similar to women 
older than 60 (Zhou et al., 1992). Studies in experimental animals have established that 
testosterone levels are negatively correlated with the duration of the action potential (Pham 
et al., 2001) and other researchers reported that dihydrotestosterone administration in 
castrated male rabbits shortened QT interval (Liu et al., 2003). 
This information indicates that testosterone is a regulator of sex differences in the action 
potential duration, ventricular repolarization and propensity to ventricular arrhythmias. In 
isolated cardiomyocytes has been established that testosterone increases the expression of ┚-
adrenergic receptors, L-type calcium channel and sodium-calcium exchanger (Golden et al., 
2004). Moreover, testosterone increases by 30% the density of repolarizing potassium 
currents, which is due to changes in both gating kinetics of the delayed rectifier potassium 
currents (Ikr) and  shortening the duration of the QT interval (Liu et al., 2003)  
Testosterone has been shown to interact directly with the NO system. Activation of this 
pathway induces shortening in the duration of the action potential by activating the slow 
component of delayed rectifier potassium current (Iks) and inhibiting L-type calcium 
currents (Ica,L) (Bai et al., 2004, 2005). 
4. Androgen-mediated cardiac hypertrophy 
The most striking evidence of cardiac effect of androgens is the case of highly conditioned 
athletes, which have died by sudden cardiac death. Post mortem examinations indicated 
anatomical abnormalities in the heart, known as hypertrophic cardiomyopathy (Maron et 
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al., 1978, 1980). Thus, it was assumed that elevated testosterone administration induces 
cardiac hypertrophy. 
Cardiac hypertrophy is an adaptive mechanism to enhance cardiac output in response to 
cardiovascular challenges. Cardiac hypertrophy is produced in response to several patho-
physiological conditions, such as mechanical stretching or neuro-hormoral deregulation. 
This process is characterized by increases in cardiomyocyte size and protein synthesis, as 
well as by the re-expression of various fetal genes (Frey & Olson, 2003; Izumo et al., 1987). 
At the cellular level, cardiomyocytes depend of the activation of several signalling pathways 
related to cell growth, which are crucial for the development of cardiac hypertrophy. These 
pathways involve both androgen receptors as well as intracellular signalling pathways. 
4.1 Androgen receptor in hypertrophy 
Cellular effects of testosterone depend on activation of androgen receptor, which is localized in 
cytoplasm and acts as a transcriptional factor when it binds testosterone. Marsh et al. have 
shown that androgens produce cardiac hypertrophy by a direct, receptor-specific mechanism 
(Marsh et al., 1998). They have also revealed that androgens regulate functional expression of 
an L-type calcium channel in isolated rat ventricular cardiomyocytes, leading to a modulation 
of cardiac performance in males. Li et al. reported that either castration or  administration of 
flutamide, an androgen receptor antagonist, markedly attenuated cardiac hypertrophy and 
fibrosis in guanylyl cyclase-A knock-out male mice (Li et al., 2004). In baroreceptor-denervated 
rats, left ventricular hypertrophy is gender-dependent and elevated testosterone stimulates 
cardiac hypertrophy (Cabral et al., 1988a, 1988b). Moreover, in vitro studies provide evidence 
that androgens induce hypertrophic growth in cultured cardiomyocytes, suggesting that the 
growth promoting effect is direct (Marsh et al., 1998). The hypertrophic effects of testosterone 
are associated with increased protein synthesis mediated by the androgen receptor and 
specific nuclear coactivators related to cell growth (Hickson et al., 1984). 
4.2 Intracellular signaling pathways 
Pro-hypertrophy stimuli activate diverse intracellular signaling pathways. Activation of 
these pathways by androgens could lead to long-term cellular effects by activation of co-
transcriptional modulators. Induction of multiple signaling pathways in cardiac 
hypertrophy has been described as follows:  
Ca+2 /Calcineurin/NFAT pathway 
Calcium ion (Ca+2) is one of the most diverse and important intracellular second messenger 
as well as a key element in the excitation-contraction coupling of cardiac muscle. Ca+2 has 
been related to cardiac hypertrophy, because of its ability to promote the activation of the 
protein phosphatase calcineurin through establishment of Ca+2/calmodulin complex 
(Heineke & Molkentin, 2006). Calcineurin promotes the translocation of the nuclear factor of 
activated T cells (NFAT) from cytoplasm to nucleus. NFAT family proteins are responsible 
for the expression of c-fos, c-jun and c-myc, early fetal genes; which are expressed during 
fetal development. These are silenced in adult stages and then re-expressed during cardiac 
hypertrophy, reason why they are considered as hypertrophic markers (Frey & Olson, 2002, 
2003; Heineke & Molkentin, 2006). 
PI3K/Akt/GSK3- β pathway 
Another cellular pathway involved in cardiac hypertrophy is PI3-K (Phosphoinositide 3-
kinase)/Akt proteins. This signalling pathway has been related to cell survival and 
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proliferation in almost all cell types. However, the up-regulation of the pathway by several 
stimuli induces cardiac hypertrophy. One of the most common downstream targets of Akt is 
the protein kinase GSK3-┚ (Glycogen Synthase Kinase 3-┚) (Antos et al., 2002). Activated 
GSK3-┚ phosphorylates several members of NFAT family, which promotes their 
translocation from nucleus to cytoplasm. Akt phosphorylates and inhibits GSK3-┚, which 
increases the residence of NFAT in the nucleus. Also, Akt has the ability to phosphorylate 
the protein mTOR (mammalian target of rapamycin), another downstream target of 
PI3K/Akt pathway. In cardiac cells, protein synthesis is highly regulated by mTOR, which 
stimulates protein translation and ribosome biosynthesis (Proud, 2004). mTOR lies upstream 
of critical translation regulators such as the 40S ribosomal protein S6 kinase 1 (S6K1) and the 
eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Activation of the mTOR pathway 
is a critical step to induce cardiac hypertrophy in vitro (Altamirano et al., 2009; Takano et al., 
1996) and in vivo (Shioi et al., 2003). 
G-protein-coupled receptors pathway 
Plasma membrane G-protein G-protein-coupled receptors (GPCR) are crucial for cardiac 
function and hypertrophic growth. Both G┙s and G┙q are sufficient to produce cardiac 
hypertrophy. G┙s induces the synthesis of cAMP and PKA activation, which could induce 
hypertrophy. G┙q promotes the activation of the protein phopholipase C (PLC) and IP3 
production, which induces intracellular Ca+2 oscillations and hence, the activation of 
different proteins responsible of cardiac hypertrophy, such as calcineurin (Heineke & 
Molkentin, 2006). 
These signalling pathways are related to the hypertrophic growth of cardiomyocytes. It has 
been described that testosterone induces intracellular Ca2+ increase through a nongenomic 
action mechanism, as we discussed earlier in this chapter. Studies in cultured 
cardiomyocytes show that through a nongenomic mechanism, testosterone is implicated in 
the activation of a membrane receptor coupled to a G┙q protein, thus resulting in the 
production of IP3 and Ca+2 release from endoplasmic reticulum (Vicencio et al., 2006). Then, 
calcium oscillations induce the activation of the mitogen-activated protein kinase ERK 1/2, 
which in turns phosphorylates mTOR, promoting hypertrophic cardiac growth (Altamirano 
et al., 2009). 
Aside from classical action mechanism for testosterone, non-classical effects also are 
implicated in cardiac hypertrophy development has been described. The establishment of 
testosterone-androgen receptor complex acts as a transcriptional factor for the expression of 
different genes and proteins necessary for protein synthesis, energy production and cell 
growth, which are crucial for hypertrophic growth.  
4.3 Cardiac remodelling 
Cardiac remodelling involves changes in the structure, mass and function of the heart, 
mainly due to increase in the number of myofibrils or cardiomyocyte hypertrophy. 
Proliferation of cardiac fibroblasts and consequent increase in the extracellular matrix is 
called cardiac fibrosis. The balance between synthesis and degradation of different collagen 
types determine the content of extracellular matrix proteins. Cardiac fibrosis increases the 
stiffness of the heart chambers, which produce high end diastolic pressure. If this event is 
persistent, leads to progressive and irreversible cardiac damage and heart failure. 
Controversial information exists about the role of sex hormones on cardiac remodelling 
during cardiac hypertrophy, including fibrosis. However, these differences are manifested 
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as gender differences in cardiac remodelling. Heart size of men is bigger than women, even 
when is corrected for body weight. Men also have higher incidence of fibrosis; however 
direct effects of androgens are not clear. The increase in cardiac mass is higher in men from 
puberty and has been shown that estrogens have preventive effects on cardiac hypertrophy 
(Weinberg et al., 1999). In castrated mice, administration of androgen receptor antagonists 
does not abolish the sex differences in heart size or cardiac fibrosis (Li et al, 2004), 
suggesting that androgens are not the only determinants for these differences. Negative 
consequences of fibrosis are mediated mainly by local effect of the renin-angiotensin system. 
Angiotensin II regulates differentiation and proliferation of ventricular fibroblasts and 
synthesis of extracellular matrix, which consist mainly of collagen type I and III (Krenning et 
al., 2010). The synthesis of collagen type I and III by fibroblasts is stimulated by TGF-┚1 and 
inhibited by androgens (Ikeda et al., 2005). Cardiac fibroblasts express androgen receptor, 
which suggest a role for androgens during cardiac remodelling. Experimental evidence in 
androgen receptor knockout (ARKO) mice show reduced ventricular volume and wall 
thickness, but no differences in blood pressure or heart rate as compared with normal 
animals (Ikeda et al., 2005). It has also been demonstrated that dihydrotestosterone 
increase atrial natriuretic peptide (ANP) secretion from neonatal rat cardiomyocytes 
(Marsh et al., 1998). Furthermore, ARKO mice show a significant reduction in ANP gene 
transcription, resulting in increased cardiac fibrosis. On the other hand, testosterone  
has been shown to increase the amount of collagen measured around coronary blood 
vessels contributing to fibrosis in male hypertensive rats independent of the renin-
angiotensin system. Cavasin et al. (2006) have determined that high testosterone levels 
enhance acute myocardial inflammation, adversely affecting myocardial healing and early 
remodelling (Cavasin et al., 2006). Even when the evidence is still controversial, 
androgens show a protective role on cardiac remodelling and protect the heart from 
maladaptive fibrosis, preventing the deleterious effects of increased pre- and after-load 
induced by angiotensin II. 
5. Cardiac metabolism 
Normal heart requires a continuous supply of energy to maintain muscle contraction as well 
as hemodynamic adaptation, survival, growth and metabolism. Neuro-hormonal activation 
is an important input for cardiovascular response to metabolic demands. Although initially 
adaptive, neuro-hormonal activation together with metabolic alterations has deleterious 
effects on cardiovascular system. 
In the heart muscle, ATP production is crucial for all cellular and contractile process. In the 
adult heart, ATP comes mainly from the ┚-oxidation of fatty acids, an oxygen dependent 
process. The 10 – 40% remaining come from glucose degradation through glycolysis, an 
oxygen independent process (Neglia et al., 2007; Stanley et al., 2005). 
┚-oxidation depends upon fatty acids uptake, which occurs through different fatty acid 
translocases located in the plasma membrane, like CD36 protein. Fatty acids must be 
transported to the mitochondria for ┚-oxidation, which occurs through the enzyme 
carinitine palmitoyl transferase-1 (CPT-1). Once inside mitochondria, fatty acids are 
oxidized to produce acetil–CoA, which will be incorporated into Krebs cycle for NADH, 
FADH2 and CO2 production. These intermediates provide oxidative power during the 
oxidative phosphorylation in mitochondria, where ATP is finally produced by ATP 
synthase complex V. 
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On the other hand, glycolysis requires glucose uptake, which occurs through the glucose 
transporters 1 and 4 (GLUT1 and GLUT4), the main glucose transporters in cardiac cells. 
Once inside the cell, the enzymes hexokinase and phosphofructokinase, the glycolysis 
pacemaker enzyme, lead the conversion of glucose to pyruvate. Through this process 2 ATP 
molecules are generated from each glucose molecule incorporated. 
However, the heart muscle is able to modify the ratio between ┚-oxidation and glycolysis in 
response to pro-hypertrophic agents (Stanley et al., 2005). For example, cardiac hypertrophy 
due to pressure overload is accompanied of a reduction in ┚-oxidation and an increase in the 
glycolytic rate as a compensatory mechanism that improves ATP production in the heart 
muscle (van der Vusse et al., 2000, 2002). In contrast, individuals with uncompensated 
diabetes usually develop a different cardiac hypertrophy, known as diabetic 
cardiomyopathy. Since diabetic patients are not able to metabolize glucose, diabetic 
cardiomyopathy is characterized by an increase in the fatty acids assimilation by cardiac 
cells, which carry cardiac lipotoxicity (van der Vusse et al., 2000). 
During heart failure, cardiac muscle is not able to produce enough ATP for cardiac 
contraction, resulting in poor contractile performance. It is common to observe heart 
failure in pathologies associated to bad glucose handling for ATP production, as insulin 
resistance and diabetes. Metabolic syndrome, which comprehends both pathologies, has 
been correlated with low testosterone blood levels (Saad & Gooren, 2009, 2011). It has 
been recently postulated that decrease in testosterone is a link between metabolic 
syndrome and heart failure. Clinical trials have demonstrated that the administration of 
testosterone at physiological concentrations improved insulin sensitivity, reduced 
glycaemia and central obesity, and heart failure progression in men suffering metabolic 
syndrome (Cook & Romashkan, 2011). In addition to clinical trials, there are new studies 
related to testosterone effects on glucose metabolism. It has been described that 
testosterone is necessary to maintenance insulin and glucose concentration in blood. 
Recent reports have shown an important role for testosterone in the mobilization of 
glucose transporter GLUT4 to the plasma membrane in skeletal muscle, liver and fat 
tissue (Muthusamy et al., 2007, 2009). 
In spite, elevated testosterone administration in humans is usually associated with the 
development of cardiac hypertrophy and heart failure; there are several studies that 
examine the relationship between the testosterone supplementation and heart failure with 
non positive correlation between them. Nowadays, several clinical trials lead to propose that 
testosterone supplementation at physiological doses could be a treatment for men with 
metabolic syndrome and heart failure (Pugh et al., 2000). The effect of testosterone as a 
metabolic modulator could improve insulin sensitivity and glucose uptake in the heart, 
which could lead to an increase in ATP production when cardiac output increases. 
However, evidences about the metabolic properties of testosterone on heart muscle come 
from observational studies. Research on the molecular mechanisms implicated in the 
metabolic testosterone actions is required.  
6. Integrated model for androgen action 
Androgens diffuse across plasma membrane due to their lipophilic nature. Once inside the 
cell, they are recognized by the cytosolic androgen receptor, which forms a complex with its 
ligand. This complex works as a transcription factor, which translocates to cell nucleus, 
binds to DNA and promotes the activation of several genes (Beato, 1989). This is called the 
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classic or genomic androgen response pathway. On the other hand, it has been reported that 
androgens, exert a rapid, non-genomic effect mediated by a putative plasma membrane 
receptor. Its activation implicates participation of kinases, intracellular calcium oscillations 
and transcription factor activation, among other fast events.  
Cardiomyocytes are terminally differentiated cells. Cardiac hypertrophy is characterized by 
an increase in cell size and protein synthesis and reactivation of a fetal gene program. 
Emerging evidence indicate that androgen action involves a crosstalk between genomic and 
nongenomic mechanisms. These could imply a two-step process, where both non-genomic 
and genomic effects occur sequentially (Figure 2). First, fast effects would be generated at 
the plasma membrane level with second messenger participation. Second, there would be 
gene activation; the pathways used by each cell type could provide specificity to the signal 
through a cooperative mechanism, which can act in a concerted form. 
 
 
Fig. 2. Integrated mechanism for testosterone effects in cardiomyocytes. In cardiomyocytes, 
testosterone activates plasma membrane androgen receptors coupled to heterotrimeric Gq 
protein. G┚┛ dimers activate phospholipase C (PLC), which locally produces inositol IP3 
thus activating IP3 receptors (IP3R). The consequent Ca2+ increase leads to the activation of 
several pathways, including the MEK/ERK/mTOR axis. These responses combined induce 
a series of genomic changes that lead to increased gene expression and increased protein 
synthesis, ultimately leading to cardiac hypertrophy. 
While studying these hypertrophy effects on cardiomyocytes, our laboratory determined 
that testosterone uses a cooperative mechanism between the genomic and nongenomic 
pathways to produce the hypertrophic growth of cardiac cells. Thus, with normal levels of 
androgens the interactions among signaling pathways lead to the maintained health of 
cardiac cells, whereas high doses recruit additional signals which are hypertrophic. As 
www.intechopen.com
 
Cardiovascular Effects of Androgens 
 
73 
depicted in Figure 2, testosterone activates a plasma membrane G-protein coupled receptor, 
a signaling pathway that results in a nongenomic mechanism. Activation of this pathway 
facilitates the hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase C, 
thereby generating diacylglycerol and IP3. IP3 mediates opening of IP3 receptors in the 
sarcoplasmatic reticulum, which in turn produce rapid (1-5 min) Ca2+ release (Vicencio et al., 
2006). Similar effects of testosterone have been identified in T-cells, skeletal muscle and 
neuroblastoma cells (Benten et al., 1999; Estrada et al., 2003, 2006). In cardiomyocytes, 
nongenomic signals activate the extracellular signal-regulated kinase (ERK) and the mTOR 
pathways. Activation of Ca2+/ERK/mTOR axis is independent of androgen receptor. 
The anabolic properties of testosterone indicate that this hormone regulate multiple genes 
involved in growth and metabolism. Traditionally, ligand-dependent androgen receptors 
act on DNA within the nucleus and in this compartment there is cross-talk among the 
nuclear receptors and cytosolic signaling. We have determined that testosterone induce a 
hypertrophic pattern in cardiomyocytes, evaluated as increase in the expression of fetal 
proteins, cardiomyocyte size, and protein synthesis. Hypertrophy effects of testosterone 
were blocked by either inhibition of mTOR or androgen receptor (Altamirano et al., 2009). 
We propose that cell growth produced by androgens require both androgen receptor 
activity and translation control through mTOR signaling pathway. Thus, both mTOR 
pathway and androgen receptor could control protein synthesis by a coordinated 
mechanism, where mTOR regulates translation and the intracellular androgen receptor 
regulates gene expression. 
7. Perspective 
The role of sex steroid hormones in modulating cardiovascular function is of the highest 
importance, given that androgen deficiency is strongly associated with common medical 
conditions including metabolic syndrome, obesity, diabetes, hypertension and 
atherosclerosis.  However, cardiovascular side effects of high doses of anabolic/androgen 
steroid reduce its actual therapeutic use. Research in this field is necessary to know the real 
cardiovascular effects of androgens and to elaborate future optimal therapeutic replacement 
protocols. 
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